A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery

Du, Chunyang; Deng, Dawei; Shan, Lingling; Wan, Shouhong; Cao, Jie; Tian, Jie; Achilefu, Samuel; Gu, Yueqing

doi:10.1016/j.biomaterials.2013.01.041

Cited by 207 publications

(158 citation statements)

References 35 publications

Supporting

Mentioning

155

Contrasting

Order By: Relevance

“…Cancer is still one of the most devastating diseases, with more than 10 million cases every year (5), and thus remains the focus of interest of basic and clinical research. Conventional anticancer therapies are often associated with harmful side effects on healthy cells and hold the risk of secondary cancer, in consequence the clinical application is limited (20,30). Recent studies showed that redox-active CNPs exhibit a significant antitumor activity in several cancer cell lines (7,8).…”

Section: Discussionmentioning

confidence: 99%

“…It belongs to the most effective cancer drugs ever developed, however the clinical use of doxorubicin is restricted because of its diverse toxic effects in healthy cells and tissues (19,20). The antitumor activity of doxorubicin is mainly mediated by several interactions with genomic DNA leading to DNA damage, cell-cycle arrest and, subsequently, to apoptosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles—A Novel Aspect in Cancer Therapy

Sack

Alili

Karaman

et al. 2014

Molecular Cancer Therapeutics

128

View full text Add to dashboard Cite

Nanotechnology is becoming an important field of biomedical and clinical research and the application of nanoparticles in disease may offer promising advances in treatment of many diseases, especially cancer. Malignant melanoma is one of the most aggressive forms of cancer and its incidence is rapidly increasing. Redox-active cerium oxide nanoparticles (CNP) are known to exhibit significant antitumor activity in cells derived from human skin tumors in vitro and in vivo, whereas CNP is nontoxic and beyond that even protective (antioxidative) in normal, healthy cells of the skin. As the application of conventional chemotherapeutics is associated with harmful side effects on healthy cells and tissues, the clinical use is restricted. In this study, we addressed the question of whether CNP supplement a classical chemotherapy, thereby enhancing its efficiency without additional damage to normal cells. The anthracycline doxorubicin, one of the most effective cancer drugs, was chosen as reference for a classical chemotherapeutic agent in this study. Herein, we show that CNP enhance the antitumor activity of doxorubicin in human melanoma cells. Synergistic effects on cytotoxicity, reactive oxygen species generation, and oxidative damage in tumor cells were observed after co-incubation. In contrast to doxorubicin, CNP do not cause DNA damage and even protect human dermal fibroblasts from doxorubicin-induced cytotoxicity. A combination of classical chemotherapeutics with nongenotoxic but antitumor active CNP may provide a new strategy against cancer by improving therapeutic outcome and benefit for patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles—A Novel Aspect in Cancer Therapy

Sack

Alili

Karaman

et al. 2014

Molecular Cancer Therapeutics

128

View full text Add to dashboard Cite

show abstract

“…These studies showed that MMP inhibitors that were loaded with nanoparticles were localized in inflammation or pathological regions (127)(128)(129)(130)(131). However, drug-loaded nanoparticles are usually toxic and can cause adverse effects because of exposed in the circular to deliver.…”

Section: Aamentioning

confidence: 99%

Molecular targets in aortic aneurysm for establishing novel management paradigms

Zhu

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Aortic aneurysm (AA) is a lethal disease and presents a large challenge for surgeons in the clinic.Although surgical management remains the major choice of AA, operative mortality remains high. With advances in understanding of the mechanisms of AAs, molecular targets, such as matrix metalloproteinases (MMPs), D-dimer, and inflammation markers, including C-reactive protein, interleukins and phagocytes, are important in the pathology of development of AA. These markers may become important for improving the diagnostic quality and provide more therapeutic choices for treatment of AA. Although these new markers require long-term trials before they can be translated into the clinic, they can still be helpful in determining new directions. The main aim of this review is to discuss the current findings of molecular targets in progression of AA and discuss the potential application of these new targets for managing this disease.

show abstract

“…9,21 Among the most useful acid-labile linkers, cis-aconityl acid is frequently used when trying to design an ideal drug delivery system. 22 Compared with a nonconjugated system, a drug in this delivery system shows enhanced antitumor activity and a relative reduction in nonspecific toxicity to normal tissue. 22 As conventional anticancer drugs usually have severe toxicity, low selectivity and many adverse effects, it is necessary to combine them with some candidate ligands to deliver selectively anticancer drugs to tumor cells.…”

Section: Introductionmentioning

confidence: 99%

pH-sensitive Au–BSA–DOX–FA nanocomposites for combined CT imaging and targeted drug delivery

Huang

Yang

Liu

et al. 2017

IJN

View full text Add to dashboard Cite

Albumin-based nanoparticles (NPs) as a drug delivery system have attracted much attention owing to their nontoxicity, non-immunogenicity, great stability and ability to bind to many therapeutic drugs. Herein, bovine serum albumin (BSA) was utilized as a template to prepare Au–BSA core/shell NPs. The outer layer BSA was subsequently conjugated with cis -aconityl doxorubicin (DOX) and folic acid (FA) to create Au–BSA–DOX–FA nanocomposites. A list of characterizations was undertaken to identify the successful conjugation of drug molecules and targeted agents. In vitro cytotoxicity using a cell counting kit-8 (CCK-8) assay indicated that Au–BSA NPs did not display obvious cytotoxicity to MGC-803 and GES-1 cells in the concentration range of 0–100 μg/mL, which can therefore be used as a safe drug delivery carrier. Furthermore, compared with free DOX, Au–BSA–DOX–FA nanocomposites exhibited a pH-sensitive drug release ability and superior antitumor activity in a drug concentration-dependent manner. In vivo computed tomography (CT) imaging experiments showed that Au–BSA–DOX–FA nanocomposites could be used as an efficient and durable CT contrast agent for targeted CT imaging of the folate receptor (FR) overexpressed in cancer tissues. In vivo antitumor experiments demonstrated that Au–BSA–DOX–FA nanocomposites have selective antitumor activity effects on FR-overexpressing tumors and no adverse effects on normal tissues and organs. In conclusion, the Au–BSA–DOX–FA nanocomposite exhibits selective targeting activity, X-ray attenuation activity and pH-sensitive drug release activity. Therefore, it can enhance CT imaging and improve the targeting therapeutic efficacy of FR-overexpressing gastric cancers. Our findings suggest that Au–BSA–DOX–FA nanocomposite is a novel drug delivery carrier and a promising candidate for cancer theranostic applications.

show abstract

A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery

Cited by 207 publications

References 35 publications

Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles—A Novel Aspect in Cancer Therapy

Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles—A Novel Aspect in Cancer Therapy

Molecular targets in aortic aneurysm for establishing novel management paradigms

pH-sensitive Au–BSA–DOX–FA nanocomposites for combined CT imaging and targeted drug delivery

Contact Info

Product

Resources

About

A pH-sensitive doxorubicin prodrug based on folate-conjugated BSA for tumor-targeted drug delivery

Cited by 207 publications

References 35 publications

Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles—A Novel Aspect in Cancer Therapy

Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles—A Novel Aspect in Cancer Therapy

Molecular targets in aortic aneurysm for establishing novel management paradigms

pH-sensitive Au&ndash;BSA&ndash;DOX&ndash;FA nanocomposites for combined CT imaging and targeted drug delivery

Contact Info

Product

Resources

About

pH-sensitive Au–BSA–DOX–FA nanocomposites for combined CT imaging and targeted drug delivery